Mirum Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
MIRM$94.42+1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(In thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Net loss | $(23,363) | $(87,942) | $(163,415) |
| Other comprehensive income (loss): | |||
| Unrealized gain on available-for-sale investments | 10 | 130 | 230 |
| Cumulative translation adjustments | 714 | (2,147) | 1,631 |
| Comprehensive loss | $(22,639) | $(89,959) | $(161,554) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.